Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02724163 Phase III Gemtuzumab ozogamicin Busulfan + Fludarabine Cytarabine Cytarabine + Fludarabine Cytarabine + Daunoxome Busulfan + Cyclophosphamide Cytarabine + Mitoxantrone International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01) Recruiting NZL | GBR | FRA | AUS 2
NCT02790515 Phase II Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim Provision of TCRgammadelta T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Recruiting USA 0
NCT03164057 Phase II Etoposide Filgrastim Dexrazoxane Daunorubicin Idarubicin Fludarabine Asparaginase Cytarabine Sorafenib Mitoxantrone Decitabine Azacitidine A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04055844 Phase II Decitabine + Ruxolitinib Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS Completed USA 0
NCT04326439 Phase II Cytarabine + Etoposide Cytarabine + Etoposide + Sorafenib Asparaginase Erwinia chrysanthemi + Cytarabine + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin + Sorafenib Cytarabine + Mitoxantrone + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin Asparaginase Erwinia chrysanthemi + Cytarabine Cytarabine + Mitoxantrone AflacLL1901 (CHOA-AML) Terminated USA 0
NCT05854966 Phase II CPI-613 + Metformin CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Not yet recruiting USA 0
NCT05955261 Phase II Azacitidine + Cytarabine + Daunorubicin + Etoposide + Fludarabine + Gemtuzumab ozogamicin + Gilteritinib + Idarubicin + Venetoclax Cytarabine + Daunorubicin + Etoposide + Fludarabine + Gemtuzumab ozogamicin + Gilteritinib + Idarubicin + mitoxantrone hydrochloride + Venetoclax Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin + Gilteritinib + mitoxantrone hydrochloride + Venetoclax A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia Recruiting USA 0